Black Diamond Reports Phase 2 Results for BDTX-1535 in Lung Cancer, Targets FDA Approval Path
Portfolio Pulse from Benzinga Newsdesk
Black Diamond Therapeutics reported promising Phase 2 results for BDTX-1535 in treating EGFR-mutant non-small cell lung cancer, showing a 42% response rate and good tolerability. The company aims for FDA approval and plans to release more data in 2025.
September 23, 2024 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Black Diamond Therapeutics' Phase 2 trial of BDTX-1535 shows promising results in lung cancer, with a 42% response rate and good tolerability. The company is targeting FDA approval and plans to release more data in 2025.
The positive Phase 2 results for BDTX-1535, including a 42% response rate and good tolerability, suggest potential for FDA approval, which could significantly boost Black Diamond's stock. The company's plan to release more data in 2025 further supports a positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100